Global CAR T-Cell Therapy Competitive Landscape Professional Research Report 2024
Research Summary
CAR T-cell therapy, also known as chimeric antigen receptor T-cell therapy, is an innovative and personalized immunotherapy approach used in the treatment of certain types of cancer. It involves modifying a patient's own T cells, which are a type of immune cell, to express a synthetic receptor called a chimeric antigen receptor (CAR) on their surface. The CAR is designed to recognize and bind to specific proteins, known as antigens, found on cancer cells. Once the modified CAR T cells are infused back into the patient's body, they can identify and attack cancer cells that express the targeted antigen, effectively destroying the cancer cells. CAR T-cell therapy has shown remarkable success in the treatment of certain hematological malignancies, such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma. It has provided new hope for patients who have exhausted other treatment options, and its efficacy continues to be investigated in clinical trials for various other types of cancers. CAR T-cell therapy represents a promising advancement in cancer treatment, harnessing the power of the patient's own immune system to fight and potentially eradicate cancer cells.
According to DIResearch's in-depth investigation and research, the global CAR T-Cell Therapy market size will reach XX US$ Million in 2024, and is expected to reach XX US$ Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be XX US$ Million, accounting for approximately XX% of the world. It is expected to reach XX US$ Million in 2030, and the global share will reach XX%.
The major global manufacturers of CAR T-Cell Therapy include Bristol Myers Squibb, Gilead Sciences, Novartis, Autolus, Janssen, JW Therapeutics, Beijing Immunochina Pharmaceuticals, Bioray Laboratories etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.
This report studies the market size, price trends and future development prospects of CAR T-Cell Therapy. Focus on analysing the market share, product portfolio, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global CAR T-Cell Therapy market. The report data covers historical data from 2019 to 2023, base year in 2024 and forecast data from 2025 to 2030.
The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the CAR T-Cell Therapy market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of CAR T-Cell Therapy industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of CAR T-Cell Therapy Include:
Bristol Myers Squibb
Gilead Sciences
Novartis
Autolus
Janssen
JW Therapeutics
Beijing Immunochina Pharmaceuticals
Bioray Laboratories
CAR T-Cell Therapy Product Segment Include:
CD19
BCMA
CD19/CD22
Other
CAR T-Cell Therapy Product Application Include:
Non-Hodgkin Lymphoma
Multiple Myeloma
Acute Lymphoblastic Leukemia
Other
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends
Chapter 2: Global CAR T-Cell Therapy Industry PESTEL Analysis
Chapter 3: Global CAR T-Cell Therapy Industry Porter’s Five Forces Analysis
Chapter 4: Global CAR T-Cell Therapy Major Regional Market Size and Forecast Analysis
Chapter 5: Global CAR T-Cell Therapy Market Size and Forecast by Type and Application Analysis
Chapter 6: North America CAR T-Cell Therapy Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 7: Europe CAR T-Cell Therapy Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 8: China CAR T-Cell Therapy Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 9: APAC (Excl. China) CAR T-Cell Therapy Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 10: Latin America CAR T-Cell Therapy Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 11: Middle East and Africa CAR T-Cell Therapy Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 12: Global CAR T-Cell Therapy Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers
Chapter 15: Research Findings and Conclusion
Chapter 16: Methodology and Data Sources